Pharmacogenes associated with adverse reactions induced by second-generation antipsychotic drugs: A systematic review
Authors:
- Erick A. Alvarado-VeraEAErick A. Alvarado-Vera
- Angel T. AlvaradoAngel T. Alvarado
- María Saravia BartraMBMaría Saravia Bartra
- Jorge A. GarcíaJGJorge A. García
- María R. BendezúMBMaría R. Bendezú
- Juan J. Palomino-JhongJPJuan J. Palomino-Jhong
- Haydee ChávezHCHaydee Chávez
- Doris Laos-AnchanteDLDoris Laos-Anchante
- Elizabeth J. Melgar-MerinoEMElizabeth J. Melgar-Merino
- Pompeyo A. Cuba-GarcíaPCPompeyo A. Cuba-García
- Paulina Eliades Yarasca-CarlosPYPaulina Eliades Yarasca-Carlos
Open Access
- 20 November 2025
- journal article
- review article
- Published by Pensoft Publishers in Pharmacia
- Vol. 72, 1-9
Abstract
Pharmacogenes are specific genes that determine how an individual will respond to medication. Some of these genes have been linked to adverse reactions caused by second-generation antipsychotics. A literature search was conducted using relevant terms across the PubMed, CTG Studies, and Scopus databases. The included articles examined pharmacogenes associated with adverse reactions induced by second-generation antipsychotics. The articles were published between 2015 and 2025. A total of 12 observational studies were included. The review protocol is registered in PROSPERO (CRD420251035803). The studies demonstrated an association of CYP1A2 with adverse reactions induced by aripiprazole ( p < 0.035), clozapine ( p = 0.009, p = 0.042, and p = 0.046), and olanzapine ( p < 0.05). CYP2C19 was associated with clozapine-induced metabolic syndrome ( p < 0.01). CYP3A4 was associated with clozapine-induced hyperglycemia (χ² = 0.1), and CYP3A5 was associated with quetiapine ( p < 0.007). CYP2D6 was linked to adverse reactions induced by clozapine ( p = 0.039), olanzapine ( p = 0.047), risperidone ( p = 0.021 and p = 0.02), and quetiapine ( p = 0.003). This review shows that certain allelic variants of pharmacogenes are associated with adverse reactions to second-generation antipsychotics. This finding applies to patients with impaired metabolism. We recommend conducting longitudinal multicenter studies before promoting allelic variants of pharmacogenes as predictive biomarkers.Keywords
This publication has 55 references indexed in Scilit:
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor AntidepressantsClinical Pharmacology & Therapeutics, 2023
- Psychiatric diagnosis and treatment in the 21st century: paradigm shifts versus incremental integrationWorld Psychiatry, 2022
- Mortality in people with schizophrenia: a systematic review and meta‐analysis of relative risk and aggravating or attenuating factorsWorld Psychiatry, 2022
- Internalizing psychopathology and all‐cause mortality: a comparison of transdiagnostic vs. diagnosis‐based risk predictionWorld Psychiatry, 2021
- Alcohol intake potentiates clozapine adverse effects associated to CYP1A2*1C in patients with refractory psychosisDrug Development Research, 2020
- Safety and cardiovascular effects of multiple‐dose administration of aripiprazole and olanzapine in a randomised clinical trialHuman Psychopharmacology: Clinical and Experimental, 2020
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA‐B Genotypes and Phenytoin Dosing: 2020 UpdateClinical Pharmacology & Therapeutics, 2020
- Worldwide Distribution of Cytochrome P450 Alleles: A Meta‐analysis of Population‐scale Sequencing ProjectsClinical Pharmacology & Therapeutics, 2017
- Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 updateClinical Pharmacology & Therapeutics, 2016
- CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side EffectsBulletin of Experimental Biology and Medicine, 2016